Patents by Inventor David Andrew Coates

David Andrew Coates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS USEFUL FOR INHIBITING CDK7
    Publication number: 20190144456
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Vipin Yadav
  • Amino pyrimidine SSAO inhibitors
    Patent number: 10287270
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 14, 2019
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • N-[3-[2-AMINO-5-(1,1-DIFLUOROETHYL)-4,4A,5,7-TETRAHYDROFURO[3,4-D][1,3]OXAZIN-7A-YL]-4-FLUORO-PHENYL-5-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE AND ITS (4AR,5S,7AS) ISOMER AS A SELECTIVE BACE1 INHIBITOR FOR TREATING E.G. ALZHEIMER'S DISEASE
    Publication number: 20190106434
    Abstract: The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-(trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserted here] or a pharmaceutically acceptable salt thereof and in particular its (4aR,5S,7aS) isomer as a selective BACE1 inhibitor for treating e.g. Alzheimer's disease and the progression of mild cognitive impairment to Alzheimer's disease.
    Type: Application
    Filed: May 12, 2017
    Publication date: April 11, 2019
    Inventors: David Andrew Coates, Erik James Hembre
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20180325873
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 15, 2018
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • AMINO PYRIMIDINE SSAO INHIBITORS
    Publication number: 20180297987
    Abstract: The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: David Andrew Coates, Luo Heng Qin, Yi Wei, Jingye Zhou
  • Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
    Patent number: 10080758
    Abstract: The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: September 25, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Craig Daniel Wolfangel
  • 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives
    Patent number: 9920056
    Abstract: The present invention provides compounds of Formula 1, where A is selected from and R1, R2 and R3 are defined in the specification, or a pharmaceutically acceptable salt thereof, methods of using the compounds to treat diabetes, and processes for the synthesis of the compounds.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 20, 2018
    Assignee: Eli Lilly and Company
    Inventors: Thomas James Beauchamp, David Andrew Coates, Maria Angeles Martinez-Grau, Miguel Angel Toledo
  • TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE
    Publication number: 20170368071
    Abstract: The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.
    Type: Application
    Filed: January 22, 2016
    Publication date: December 28, 2017
    Inventors: David Andrew Coates, Craig Daniel Wolfangel
  • Tetrahydropyrrolo[3,4-D][1,3]thiazine-derivative as BACE inhibitor
    Patent number: 9828390
    Abstract: The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Alzheimer's disease (BACE inhibitor).
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: November 28, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Pablo Garcia Losada
  • A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR
    Publication number: 20170233410
    Abstract: The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE inhibitor).
    Type: Application
    Filed: September 8, 2015
    Publication date: August 17, 2017
    Applicant: Eli Lilly and Company
    Inventors: David Andrew COATES, Pablo Garcia LOSADA
  • CGRP receptor antagonists
    Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044163
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL] CARBOXYLIC ACID DERIVATIVES
    Publication number: 20160368922
    Abstract: The present invention provides compounds of Formula 1, where A is selected from and R1, R2 and R3 are defined in the specification, or a pharmaceutically acceptable salt thereof, methods of using the compounds to treat diabetes, and processes for the synthesis of the compounds.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 22, 2016
    Inventors: Thomas James Beauchamp, David Andrew Coates, Maria Angeles Martinez-Grau, Miguel Angel Toledo
  • METHODS FOR IMPROVING CHICKEN PRODUCTION
    Publication number: 20150203471
    Abstract: The invention provided methods of improving the growth performance of and/or increasing the meat obtainable from chicken, and/or reducing gas emissions from a chicken or chicken raising operation, comprising administering to the chicken an effective amount of Compound 5 or a physiologically acceptable salt thereof. Also included in the invention are oral chicken feed compositions comprising an effective amount of the above compound, and the crystalline hemifumarate anhydrous salt Form II of the above compound.
    Type: Application
    Filed: September 24, 2013
    Publication date: July 23, 2015
    Applicant: ELI LILLY AND COMPANY
    Inventors: Djamel Aissat, Brian D. Burke, David Andrew Coates, Jeffrey Glen Sherman
  • 3,4-dihydroisoquinolin-2(1)-yl compounds
    Patent number: 8962654
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, David Andrew Coates, Junliang Hao, Joseph Herman Krushinski, Jr., Matthew Robert Reinhard, John Mehnert Schaus, Craig Daniel Wolfangel
  • 3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS
    Publication number: 20140357664
    Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.
    Type: Application
    Filed: May 27, 2014
    Publication date: December 4, 2014
    Applicant: Eli Lilly and Company
    Inventors: Christopher David BEADLE, David Andrew COATES, Junliang HAO, Joseph Herman KRUSHINSKI, JR., Matthew Robert REINHARD, John Mehnert SCHAUS, Craig Daniel WOLFANGEL
  • SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS
    Publication number: 20140275049
    Abstract: The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 18, 2014
    Inventors: Thomas John Bleisch, David Andrew Coates, Norman Earle Hughes, Scott Alan Jones, Bryan Hurst Norman
  • Mineralocorticoid receptor antagonist and methods of use
    Patent number: 8658638
    Abstract: The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering Compound (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: February 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Konstantinos Gavardinas, Prabhakar Kondaji Jadhav